Amy Emerson
Executive Director and Director of Clinical Research of MAPS Public Benefit Corporation

Amy earned her BS in genetics and cell biology from Washington State University in 1992. Prior to her work at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MPBC) she worked in clinical development and research beginning in 1993. Amy's previous experience is in the fields of immunology (Applied Immune Sciences), oncology (RPR), and vaccine development (Chiron and Novartis). Amy worked with MAPS as a volunteer starting in 2003 facilitating the development of the MDMA clinical program. In 2009 she began managing the Clinical Research group at MAPS. She is currently the Executive Director and Director of Clinical Research of MAPS Public Benefit Corporation.


Clinical Research Department 
Berra Yazar-Klosinski, Ph.D.
MAPS Associate Director of Clinical Research
Berra earned her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She utilizes her scientific training and experience in for-profit pharmaceutical research to support MAPS' work to develop, design, and implement clinical psychedelic research in the U.S and beyond. She earned her B.S. in Biological Science from Stanford University in 2001, with an emphasis on the neurobiology of drugs. Prior to entering graduate school, Berra worked as a Research Associate with Geron Corporation screening for drugs that activate telomerase, and with Millennium Pharmaceuticals on Phase 1 clinical trials in patients with Acute Myeloid Leukemia. Berra joined MAPS in 2009 in order to work with an organization where profit wouldn't dictate the agenda of scientific research.​ She has been actively involved in the Phase 1/2/3 clinical development of MDMA-assisted psychotherapy, most recently as Associate Director of Clinical Research.


Alia Lilienstein, M.D., M.P.H.
MAPS Clinical Research Associate - Physician
Alia is a board-certified Family Medicine physician. She earned her B.A. in American Studies from Georgetown University in 2002, where she studied social and cultural influences on health care. Prior to medical school, she earned her Master of Public Health in Epidemiology and Biostatistics in 2004 from the University of California, Berkeley, and worked in clinical research and development at Chiron (later Novartis). She received her M.D. in 2011 from Mount Sinai School of Medicine in New York and completed residency training in Family Medicine at Cambridge Health Alliance, a Tufts- and Harvard-affiliated Accountable Care Organization. Before joining MAPS, Alia worked as a primary care doctor in Berkeley. Alia holds a certificate in Psychedelic-Assisted Therapies and Research from CIIS in San Francisco. As a family physician, Alia has borne witness to her patients’ struggles with the human condition and the effects these struggles have on their loved ones. She is passionate about helping develop better tools for psychological healing so that everyone may have the opportunity to approach themselves and others with empathy and love. ​


Alli Feduccia, Ph.D.
Clinical Data Scientist
Alli Feduccia, Ph.D., received a bachelor’s degree in Biological Psychology in 2009 from Louisiana State University. After earning a Ph.D. in Neuropharmacology from the University of Texas at Austin by utilizing rodent models to study the effects of MDMA on behavior and neurochemical release, she held a postdoctoral research position in the Preclinical Development Group at Ernest Gallo Clinic and Research Center at the University of California San Francisco where her experiments aimed to discover novel treatment strategies for alcohol dependence by elucidating the mechanisms of action of medications used to treat substance use disorders. In 2012, she received a Postdoctoral Research Training Award from the National Institutes of Health that enabled her to work on clinical trials at NIAAA/NIDA investigating novel therapeutics for alcoholism, as well as, human fMRI studies oriented to understanding the neural underpinnings of addiction. At MAPS PBC, Alli is currently serving as the Clinical Data Scientist, performing various tasks to ensure clinical data is analyzed and communicated in the highest quality for regulatory documents, scientific publications, and public presentations. She also makes online e-learning modules and creates content for a web-based learning management system to host training and educational material for site and therapy teams, Zendo Project, and other public educational outreach. Alli is passionate about starting a MAPS-sponsored trial of ayahuasca for treatment of alcohol use disorders and is currently applying her translational perspective to the development of a new protocol. Recognizing this as a monumental time in history, Alli highly regards the opportunity to participate in efforts to generate scientifically based evidence on the therapeutic and spiritual potential of psychedelics.


Julie Densmore, M.A.
Clinical Research Consultant
Julie transitioned from a MAPS volunteer to a clinical consultant in September 2017. She brings over 17 years of professional expertise in global, clinical development of oncology and infectious disease medicines gleaned in the biotechnology and pharmaceutical sectors.  Over her career she has managed the operations of Phase I - IV clinical trials, guided program strategy, developed scientific literature, and lead project teams. She has been a key contributor to four product submissions and subsequent approvals in the US and Europe. 

Julie is dedicated to pioneering novel, multi-disciplinary approaches to disease management through the intersection of public policy, personalized medicine, engineering, data science, and biology. Julie holds a M.A in Behavioral Research Methodology, a B.A. in Psychology, and a certificate in Data Science.


Gabrielle Fortier, M.P.H.
Clinical Research Associate
Gabby is a Clinical Research Associate who joins the MAPS Public Benefit Corporation (MPBC) research team at an exciting time as their clinical trials program continues to grow. Gabby earned her B.A. in International Relations from Boston University in 2013. While an undergraduate at BU Gabby worked part-time as a research assistant at the Slone Epidemiology Center where she supported numerous birth-defect and post-market vaccine surveillance studies. After graduating, Gabby decided she wanted to continue her research career and became a full-time employee at Slone while pursuing her Master’s in Public Health in the evening hours. Gabby earned her M.P.H. from BU in 2015 after completing her research practicum evaluating the community health system in Kenya. More recently, Gabby worked at a major Contract Research Organization where she supported a number of high-profile Phase 1, 2, and 3 pharmaceutical trials. Gabby is excited to bring her experience and passion for clinical research and public health to MPBC!


Connor Harada
Clinical Study Assistant
Connor Harada earned a bachelor’s degree in Cognitive Science in 2017 from the University of California Santa Cruz and is currently earning a master’s degree in Psychology from Palo Alto University. Prior to joining MAPS Public Benefit Corporation (MPBC), Connor worked in an artificial intelligence and human-computer interaction lab where he assisted researching emotion and stress monitoring. Connor also worked as MPBC’s clinical intern prior to officially joining the team.

At MPBC, Connor is currently serving as a Clinical Study Assistant, focusing on regulatory sciences, general administration, and clinical operations. Connor is involved in regulatory submissions, document tracking, and study support. Connor joined MPBC in order to revolutionize the common-practice, psychiatric models that are currently upheld in modern day clinical settings and believes his efforts in psychedelic research is a gateway to that goal. In Connor’s free time, he enjoys statistical analysis, sound wave and music production, and caring for his Australian Shepherd, Troy.


Charlotte Harrison
Senior Clinical Research Associate
Charlotte Harrison is an experienced clinical research professional who is thrilled to be contributing to psychedelic research at MAPS Public Benefit Corporation. Prior to joining MPBC, she earned her bachelor’s degree in Greek and Latin in 2012 from Tufts University while pursuing pre-medical studies. After an exciting internship working on oncology trials at Clinical Assistance Programs (CAP), she decided her skills were better suited to clinical research. She monitored and managed clinical trials in supportive cancer care, nephrology, dermatology, and cardiology at CAP, MedTrials, and Harvard Clinical Research Institute.

At MPBC, Charlotte is currently serving as a Senior Clinical Research Associate, supporting the management of MDMA and marijuana studies. She supports, trains, and monitors multiple sites, ensuring quality research and compliance. She is hopeful that her passion for improving the quality of life for those suffering with mental illness and determination to make scientific research more efficient will be beneficial to MAPS’ important and necessary work. In her free time, Charlotte can be found doing yoga, snuggling her cats, or playing board games late into the night.


Libby Heimler
Clinical Research Associate
Libby is a committed research professional with a background in Adult and Pediatric Oncology. Prior to beginning her career, she studied Psychological Science and Religious Studies at Albion College, where she received a rich and rigorous education in research design and ancient Jewish scripture. Prior positions included work on studies at Karmanos Cancer Institute, Children’s Hospital Oakland, and Genentech. After working as the Study Coordinator for a MAPS study, she joined the MAPS staff as a Clinical Research Associate. Libby is passionate about research ethics and innovations in mental health treatment, and is delighted to be a part of this dynamic team working to improve both of those things. In her free time, she can be found sewing her own clothes and quilts, knitting more hats than anyone needs, cooking, hiking, and traveling.


L. (Ilsa) Jerome, Ph.D.
Research and Information Specialist
L. (Ilsa) Jerome earned a doctorate in psychology from the University of Maryland in 1999, with an interest in social cognition. Inside and beyond formal education, Jerome immersed herself in literature on psychopharmacology and what would soon become affective and social neuroscience. Ilsa was a member of the team that developed the initial 3,4-methylenedioxymethamphetamine (MDMA) Investigator’s Brochure. Jerome was the Clinical Research and Information Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS). At MAPS Public Benefit Corporation (MPBC), Jerome has retained the title, focusing on archiving, communicating and sharing information about studies into the effects, risks and benefits of MAPS’ primary study drugs, particularly MDMA and classic psychedelics. Seeking, understanding and communicating scientific information has been at the core of this role, while the details have changed. As clinical research and information specialist, Jerome has collected and summarized research as part of designing and developing the Investigator’s Brochure and Phase 2 studies. She has assisted in the revision and management of Psychedelic Bibliography scope and content, supported and communicated with medical monitors, and communicated with researchers within and outside of MAPS and sending findings into the world as published reports. She believes in the necessity of interpreting and sharing research knowledge that will best help MPBC produce transparent, thorough and honest documents and reports, and that spotting good questions is as important as knowing good answers. Ilsa is fascinated by sound and music, and fragrance and olfaction. She spent a couple of years as a DJ at a university radio station, but remains emphatically unhip.


Rebecca Matthews
Clinical Operations Manager
Rebecca earned her BA at UC Berkeley in 2000.  Prior to her work at Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MPBC) she worked in clinical research and development at Chiron/Novartis starting in 2001, working on sepsis and monitoring and managing vaccine trials.  In 2009, she joined MAPS as a part-time contractor and has since been working with them on MDMA/PTSD studies. In 2015, Rebecca joined MPBC full-time to work on Marijuana/PTSD studies as well as continuing to support MDMA studies. ​


Allison Wilens
Clinical Systems Analyst
Allison earned her B.S. in Biopsychology in 2014 from Tufts University. She worked in the Tufts Psychopharmacology Lab for three years, conducting data collection and analysis for several projects. Her Senior Honors Thesis focused on the role of the NMDA receptor in mediating aggressive withdrawal symptoms in alcohol-dependent, outbred, male mice. She was also co-president of the Tufts chapter of Students for Sensible Drug Policy (SSDP), where she helped to pass medical amnesty reform on campus and spread awareness of the harmful side effects of the War on Drugs. Allison is currently serving as MAPS’ Clinical Study Associate, providing general administrative support to the clinical department. She considers working for MAPS to be a dream come true and relishes the opportunity to help deconstruct the damaging, reductionist paradigms of the contemporary mental health care system and to improve access to viable treatment options for those suffering from trauma- and anxiety-related disorders.
Data Management Department
Colin Hennigan, M.A.
Clinical Data Manager
Colin brings a background in research design methodology and database management to MAPS. He earned his B.A. in Political Science at the University of Chicago, with an emphasis in social theory and philosophy of science, and his M.A. in Political Science at University of California, Davis, where his graduate work focused on state sovereignty and international systems theory. Prior to joining MAPS, he worked as a Research Analyst with the Genetic Disease Screening Program at the California Department of Public Health, as a freelance technical writer, and as a private mathematics instructor. He is currently working with the MAPS Clinical Team on the creation of an online clinical database and the implementation of the Therapist Adherence Program.
Safety and Therapist Training
Michael Mithoefer, M.D.
Medical Monitor and Clinical Investigator
Michael is a psychiatrist practicing in Charleston, SC, where he divides his time between clinical research and outpatient clinical practice specializing in treating posttraumatic stress disorder (PTSD) with an emphasis on experiential methods of psychotherapy. He is a Grof-certified Holotropic Breathwork Facilitator and is trained in EMDR and Internal Family Systems Therapy. He and his wife, Annie Mithoefer, recently completed a MAPS-sponsored Phase II clinical trial testing MDMA-assisted psychotherapy for PTSD. A paper about their study was published in July 2010 in the Journal of Psychopharmacology. They are currently conducting a second trial with veterans who have PTSD resulting from service in the U.S. Armed Forces, as well as psychotherapy training programs for MAPS researchers. Dr. Mithoefer is the medical monitor for MAPS-sponsored clinical trials in Europe, the Middle East, Canada, and Colorado. Before going into psychiatry in 1995 he practiced emergency medicine for ten years, served as medical director of the Charleston County and Georgetown County Emergency Departments, and has held clinical faculty positions at the Medical University of South Carolina. He is currently board certified in Psychiatry, Emergency Medicine, and Internal Medicine.
Annie Mithoefer, B.S.N.
Annie is a Registered Nurse living in Charleston, SC, where she divides her time between clinical research and outpatient clinical practice specializing in treating posttraumatic stress disorder (PTSD) with an emphasis on experiential methods of psychotherapy. She is a Grof-certified Holotropic Breathwork Practitioner and is trained in Hakomi Therapy. Recently she and her husband, Michael Mithoefer, M.D., completed a MAPS-sponsored Phase II clinical trial testing MDMA-assisted psychotherapy for PTSD.  A paper about their study was published in the Journal of Psychopharmacology. They are currently conducting a second trial with veterans who have PTSD resulting from service in the U.S. Armed Forces, as well as psychotherapy training programs for MAPS researchers.
Shannon Clare Carlin, M.A.
MDMA Therapy Training Program Manager, Zendo Project Integration Coordinator
Shannon Clare Carlin is passionate about life and growth. She cares deeply about humankind and the natural world. Shannon is dedicated to working with people through addiction, trauma, relationship, and the body. She received her Master’s Degree in Integral Counseling Psychology from the California Institute of Integral Studies in 2014, including a practicum working with youth on moderation management for drug and alcohol use. At MPBC Shannon serves as MDMA Therapy Training Program Manager, overseeing administration and program development to educate professionals and researchers to provide MDMA-assisted psychotherapy for PTSD in approved settings. Shannon is also committed to psychedelic harm reduction, and continues to provide integration services through the Zendo Project. Shannon served as co-therapist on the MAPS-sponsored Phase 2 trial researching MDMA-assisted psychotherapy for anxiety associated with life-threatening illness, and will be a co-therapist at the Phase 3 site in Los Angeles, researching MDMA-assisted psychotherapy for severe PTSD. She is a dancer and California native. An adventurer at heart, Shannon can be found running in nature or swimming in a body of water.